Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

» Details

Guru Trades

VHT Guru Trades in

Q4 2015

VHT Guru Trades in Q4 2015

Ken Fisher 1,808 sh (New)
» More
Q1 2016

VHT Guru Trades in Q1 2016

Ken Fisher Sold Out
» More
Q4 2016

VHT Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 8,121 sh (New)
Wallace Weitz 2,076 sh (New)
» More

Ratios

vs
industry
vs
history
P/E(ttm) 22.00
VHT's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 22.00 )
Ranked among companies with meaningful P/E(ttm) only.
VHT' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.37
Current: 22
0
24.37
PE(NRI) 22.00
VHT's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 22.00 )
Ranked among companies with meaningful PE(NRI) only.
VHT' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.37
Current: 22
0
24.37
P/B 3.48
VHT's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 3.48 )
Ranked among companies with meaningful P/B only.
VHT' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.95
Current: 3.48
0
3.95

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.35
VHT's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 1.35 )
Ranked among companies with meaningful Dividend Yield only.
VHT' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.87
Current: 1.35
0
1.87
Yield on cost (5-Year) 1.35
VHT's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 1.35 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
VHT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.87
Current: 1.35
0
1.87

More Statistics

Short Percentage of Float0.00%
52-Week Range $117.80 - 138.99
Shares Outstanding (Mil)42,861,049.00
» More Articles for VHT

Headlines

Articles On GuruFocus.com
More Rate Hikes Good for the Market? Feb 20 2017 
What Does Seth Klarman Like About ViaSat? Feb 20 2017 
This Guru Loves Valeant; Should You? Feb 20 2017 
Leith Wheeler Fall Quiet Counsel: Inflation Mandate Renewal Feb 20 2017 
Spiros Segalas' Harbor Capital Appreciation Fund 4th Quarter Commentary Feb 20 2017 
Kraft Heinz Is Value Stock Picking With Unilever Feb 20 2017 
ExxonMobil: A Great Buying Opportunity Feb 20 2017 
HollyFrontier Declares Quarterly Dividend Feb 20 2017 
Gold Fields Releases 2016 Financial Results Feb 20 2017 
GM, Ford Witness China Sales Decline in January Feb 20 2017 

More From Other Websites
Pulling Back the Curtain on Danaher’s 4Q16 Operating Performance Feb 02 2017
Gilead Sciences Initiated Phase 3 Trials to Evaluate Filgotinib Feb 01 2017
Merck & Co.’s 4Q16 Estimates: Expect Flat Revenues Jan 31 2017
What Recent Developments Could Drive Eli Lilly’s Growth? Jan 27 2017
3 ETFs to Buy If You're Impressed With Johnson & Johnson's Fourth Quarter Jan 24 2017
Exploring Bristol-Myers Squibb’s Oncology Segment in 4Q16 Jan 24 2017
Why health-care stocks aren’t moving after President Trump’s Obamacare executive order Jan 24 2017
Can Q4 Earnings Revitalize Healthcare ETFs? Jan 23 2017
What to Expect from Johnson & Johnson’s 4Q16 Earnings Jan 19 2017
Is the 2017 Outlook for Healthcare Optimistic? Jan 03 2017
New Products, Recent Developments for Gilead Sciences Jan 02 2017
Edwards Lifesciences Sees Growth on Long-Term Growth Strategy Dec 15 2016
Johnson & Johnson’s Financial Guidance for 2016 Dec 13 2016
David Einhorn’s Investment Guidance at the Robin Hood Conference Dec 07 2016
Why Merck’s Immunology Business Matters Now Dec 05 2016
[$$] Gearing Up for Growth in the Trump Era Dec 03 2016
Recent R&D Developments from Merck You Won’t Want to Miss Dec 01 2016
Major Product Developments for Pfizer Dec 01 2016
Allergan’s News: Recent Acquisitions and Divestments Nov 29 2016
The Pfizer-Medivation Deal, Completed in 3Q16 Nov 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK